Michael Patrick Donovan Sells 20,000 Shares of AxoGen, Inc (NASDAQ:AXGN) Stock
AxoGen, Inc (NASDAQ:AXGN) VP Michael Patrick Donovan sold 20,000 shares of AxoGen stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $20.00, for a total transaction of $400,000.00. Following the sale, the vice president now directly owns 18,974 shares of the company’s stock, valued at approximately $379,480. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Shares of NASDAQ AXGN opened at $20.25 on Friday. AxoGen, Inc has a twelve month low of $14.13 and a twelve month high of $56.85. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.83 and a quick ratio of 8.03.
AxoGen (NASDAQ:AXGN) last announced its quarterly earnings results on Wednesday, May 8th. The medical equipment provider reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The firm had revenue of $23.30 million for the quarter, compared to the consensus estimate of $22.33 million. AxoGen had a negative return on equity of 15.58% and a negative net margin of 29.19%. The company’s revenue for the quarter was up 34.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.11) earnings per share. As a group, equities analysts expect that AxoGen, Inc will post -0.74 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Raymond James & Associates boosted its position in shares of AxoGen by 4.1% during the first quarter. Raymond James & Associates now owns 15,989 shares of the medical equipment provider’s stock worth $337,000 after purchasing an additional 634 shares in the last quarter. Legal & General Group Plc boosted its position in shares of AxoGen by 5.8% during the fourth quarter. Legal & General Group Plc now owns 12,826 shares of the medical equipment provider’s stock worth $262,000 after purchasing an additional 702 shares in the last quarter. Quantamental Technologies LLC boosted its position in shares of AxoGen by 108.3% during the first quarter. Quantamental Technologies LLC now owns 1,431 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 744 shares in the last quarter. Advisor Group Inc. boosted its position in shares of AxoGen by 130.3% during the first quarter. Advisor Group Inc. now owns 1,368 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 774 shares in the last quarter. Finally, Cutler Group LP boosted its position in shares of AxoGen by 120.0% during the first quarter. Cutler Group LP now owns 2,200 shares of the medical equipment provider’s stock worth $46,000 after purchasing an additional 1,200 shares in the last quarter. 87.40% of the stock is currently owned by institutional investors.
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Featured Story: Diluted Earnings Per Share
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.